59 completed. 59 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 59 | Completed 59 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 2 | Completed 2 |
Follow Crystal Arthropathies: new trials by email Literature Review of Crystal Arthropathies trials Research Report on Crystal Arthropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare ABP-745 Dose A, ABP-745 Dose B, Colchicine - Acute Gouty Arthritis, Gout Flare | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 479 | 2025-08-26 | 2026-10-28 |
| Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients Febuxostat Tablets, Metformin - Gout | Phase 2 | Completed | Mostafa Bahaa | 60 | 2025-05-30 | 2026-09-17 |
| A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects Febuxostat, IBI128 - Gout, Hyperuricemia | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 84 | 2024-07-10 | 2025-03-27 |
| Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia dotinurad, dotinurad + allopurinol, allopurinol - Gout, Hyperuricemia | Phase 1 / Phase 2 | Completed | Urica Therapeutics Inc. | 20 | 2023-10-04 | 2026-06-10 |
| Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout ABP-671, Allopurinol, Placebo - Gout | Phase 2 / Phase 3 | Completed | Atom Therapeutics Co., Ltd | 300 | 2023-08-11 | 2025-12-22 |
| A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) Genakumab for injection, Colchicine - Gout, Gout Initiating Urate-loweringUrate-lowering Therapy | Phase 2 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 165 | 2023-07-20 | 2025-01-01 |
| Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout D-0120, Allopurinol - Gout | Phase 2 | Completed | InventisBio Co., Ltd | 80 | 2023-04-17 | 2026-07-09 |
| An Innovative Chinese Herbal Formula for the Treatment of Gout HKIIM-KU formula, Placebo - Gout | Phase 2 | Completed | Chinese University of Hong Kong | 80 | 2022-10-11 | 2026-07-27 |
| Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout AR882 Dose 1, AR882 Dose 2, Allopurinol Tablet - Gout, Arthritis, Gouty | Phase 2 | Completed | Arthrosi Therapeutics | 42 | 2022-08-12 | 2025-01-29 |
| Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout Phase 1b: HZBio1 3mg, Phase 1b: HZBio1 6mg, Phase 1b: HZBio1 12mg - Gout | Phase 1 / Phase 2 | Completed | Hangzhou Grand Biologic Pharmaceutical, Inc. | 90 | 2022-06-23 | 2026-08-07 |
| Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients AR882 Dose 1, AR882 Dose 2, Placebo - Gout, Arthritis, Gouty | Phase 2 | Completed | Arthrosi Therapeutics | 140 | 2021-11-16 | 2023-05-12 |
| An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) ALLN-346, Placebo - Hyperuricemia, Gout | Phase 2 | Completed | Allena Pharmaceuticals | 16 | 2021-07-16 | 2023-06-22 |
| A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia ABP-671, Placebo - Gout, Hyperuricemia | Phase 2 | Completed | Atom Therapeutics Co., Ltd | 60 | 2020-11-27 | 2023-04-12 |
| Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) DYV700, Placebo, Colchicine 0.6 mg - Gout | Phase 2 | Completed | Dyve Biosciences, Inc. | 284 | 2020-02-12 | 2022-05-13 |
| Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO) - Gout Patients | Phase 2 | Completed | Arthrosi Therapeutics | 30 | 2020-02-03 | 2020-11-19 |
| A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia LC350189 formulated capsule, Placebo - Gout, Hyperuricemia | Phase 2 | Completed | LG Chem | 156 | 2019-12-02 | 2025-12-03 |
| D-0120 Safety and PK/PD Study in China D-0120 - Hyperuricemia or Gout | Phase 1 / Phase 2 | Completed | InventisBio Co., Ltd | 52 | 2019-04-18 | 2022-05-06 |
| Study of of URC102 to Assess the Efficacy and Safety in Gout Patients arm 0, arm 1, arm 2 - Gout | Phase 2 | Completed | JW Pharmaceutical | 171 | 2019-01-21 | 2021-03-18 |
| Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients SAP-001 - Gout, Hyperuricemia | Phase 2 | Completed | Shanton Pharma Co., Ltd. | 40 | 2019-01-01 | 2021-11-05 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA Verinurad, Febuxostat, Dapagliflozin - Asymptomatic Hyperuricemia | Phase 2 | Completed | AstraZeneca | 36 | 2017-10-25 | 2019-08-28 |
Showing 20 of 59. Sign in to see all of them.
Gout (55) · Hyperuricemia (27) · Arthritis, Gouty (6) · Arthritis (2) · Joint Diseases (2) · Renal Insufficiency (2) · Renal Insufficiency, Chronic (2) · Pain (1) · Rotator Cuff Tear Arthropathy (1)
Musculoskeletal Diseases (59) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (58) · Genetic Diseases, Inborn (58) · Metabolic Diseases (58) · Metabolism, Inborn Errors (58) · Nutritional and Metabolic Diseases (58) · Purine-Pyrimidine Metabolism, Inborn Errors (58) · Rheumatic Diseases (58) · Arthritis (57) · Joint Diseases (57) · Pathological Conditions, Signs and Symptoms (29) · Pathologic Processes (28) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4)
Febuxostat (16) · Allopurinol (13) · Colchicine (11) · verinurad (6) · arhalofenate (5) · canakinumab (4) · ulodesine (4) · Pegloticase (3) · Interleukin 1 Receptor Antagonist Protein (2) · Triamcinolone Acetonide (2) · URC102 (2) · diacerein (2) · tranilast (2) · Azathioprine (1) · Benzbromarone (1)
Gilead Sciences (5) · Takeda (5) · Ardea Biosciences, Inc. (4) · BioCryst Pharmaceuticals (4) · Arthrosi Therapeutics (3) · AstraZeneca (3) · Atom Therapeutics Co., Ltd (3) · JW Pharmaceutical (3) · InventisBio Co., Ltd (2) · Novartis (2) · Novartis Pharmaceuticals (2) · Nuon Therapeutics, Inc. (2) · TWi Biotechnology, Inc. (2) · Allena Pharmaceuticals (1) · Ampel BioSolutions, LLC (1)
United States (40) · Taiwan (7) · United Kingdom (7) · China (5) · Australia (4) · Canada (4) · Poland (4) · Argentina (3) · Belgium (3) · Georgia (3) · Germany (3) · Guatemala (3) · Russia (3) · South Korea (3) · Spain (3)
Alan Hollister, MD, PhD (2) · R Keenan, MD (2) · Alexandra Steinberg, MD, PhD (1) · C Tosone, MS, RAC (1) · Celina Cabale-Scholl, DPT, RN (1) · Chang-Youh Tsai (1) · Chris Smith (1) · Christopher Wynne, MBChB, Grad Dip Pharm Med (1) · Gowrie Balasubramaniam, MB ChB (1) · Hejian Zou (1) · Hyungjin Cho, MD (1) · J. Hall (1)
PMID 16911575, PMID 32951150, PMID 15751090, PMID 18759308, PMID 19141576, PMID 20533546, PMID 20660758, PMID 21169856, PMID 21372003, PMID 21439048, PMID 21540198, PMID 21572152, PMID 22223180, PMID 24122883, PMID 24602182, PMID 26742777, PMID 26894653, PMID 26989892, PMID 27980008, PMID 28877949, PMID 28975718, PMID 29531784, PMID 29657831, PMID 29848361, PMID 29868853, PMID 33075806, PMID 33605029, PMID 40420308, PMID 42816092
2015 (1)